Fluconazole (all routes except local only) - Cumulative dose > 150 mg updated on 01-29-2025

Limb defects

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S17646
R74527		 Berard (> 150 mg), 2019 Musculoskeletal malformations 1st trimester nested case control unexposed (general population or NOS) Adjustment: Yes 1.30 [0.84;2.02] 21/400   8,260/224,944 8,281 400
ref
S17830
R75209		 Molgaard-Nielsen (300 - 6000mg), 2013 Limb defects 1st trimester population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes 0.83 [0.35;1.95] 17/3,270   4,143/968,236 4,160 3,270
ref
Total 2 studies 1.18 [0.80;1.75] 12,441 3,670
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Berard (> 150 mg), 2019Berard, 2019 1 1.30[0.84; 2.02]8,28140079%ROB confusion: seriousROB selection: moderateROB classification: moderateROB missing: lowROB mesure: criticalROB reporting: moderate Molgaard-Nielsen (300 - 6000mg), 2013Molgaard-Nielsen, 2013 2 0.83[0.35; 1.95]4,1603,27021%ROB confusion: seriousROB selection: lowROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 0% 1.18[0.80; 1.75]12,4413,6700.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: > 150 mg; 2: 300 - 6000mg;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.83[0.35; 1.96]4,1603,270 -NAMolgaard-Nielsen (300 - 6000mg), 2013 1 case control studiescase control studies 1.30[0.84; 2.02]8,281400 -NABerard (> 150 mg), 2019 1 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.18[0.80; 1.75]12,4413,6700%NABerard (> 150 mg), 2019 Molgaard-Nielsen (300 - 6000mg), 2013 2 Tags Adjustment   - Yes  - Yes 1.18[0.80; 1.75]12,4413,6700%NABerard (> 150 mg), 2019 Molgaard-Nielsen (300 - 6000mg), 2013 2 All studiesAll studies 1.18[0.80; 1.75]12,4413,6700%NABerard (> 150 mg), 2019 Molgaard-Nielsen (300 - 6000mg), 2013 20.25.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.18[0.80; 1.75]12,4413,6700%NABerard (> 150 mg), 2019 Molgaard-Nielsen (300 - 6000mg), 2013 20.510.01.0